Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer

Immune checkpoint blockade against programmed cell death 1 (PD-1) and its ligand PD-L1 often induces durable tumor responses in various cancers, including non–small cell lung cancer (NSCLC). However, therapeutic resistance is increasingly observed, and the mechanisms underlying anti–PD-L1 (aPD-L1) a...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Bo, Kiyotani, Kazuma, Sakata, Seiji, Nagano, Seiji, Kumehara, Shun, Baba, Satoko, Besse, Benjamin, Yanagitani, Noriko, Friboulet, Luc, Nishio, Makoto, Takeuchi, Kengo, Kawamoto, Hiroshi, Fujita, Naoya, Katayama, Ryohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446862/
https://www.ncbi.nlm.nih.gov/pubmed/30872362
http://dx.doi.org/10.1084/jem.20180870

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446862/
https://www.ncbi.nlm.nih.gov/pubmed/30872362
http://dx.doi.org/10.1084/jem.20180870

Ejemplares similares